Sofinnova Partners Closed Its Crossover II Fund at €725 Million, Above Target, to Back Late-Stage European Life Sciences Companies:

Sofinnova Partners Closed Its Crossover II Fund at €725 Million, Above Target, to Back Late-Stage European Life Sciences Companies

Sofinnova Partners, the Paris-, London- and Milan-based life sciences venture firm, announced on November 16 the final close of Sofinnova Crossover II at €725 million ($815 million), above its original target.

The fund will back about 15 high-growth companies, focused primarily on European clinical-stage biopharma and medtech businesses that need capital to reach commercialization, with selective investments in the United States and other markets. Partner Kinam Hong told Fierce Biotech that about 80% of the fund will be invested in Europe, and that immunology and inflammation, oncology, central nervous system disorders, rare disease and cardiometabolic disease are areas of focus.

Crossover II has already started investing. Its first holdings include Ireland’s Neurent Medical, Denmark’s Hemab Therapeutics and the UK’s CellCentric. According to Fierce, the close brings Sofinnova’s assets across its strategies to more than €5 billion.

Chairman and Managing Partner Antoine Papiernik said the fund’s size reflects both the maturity of the European life sciences ecosystem and rising demand for capital that can carry companies into global markets. The predecessor fund, Crossover I, backed companies that were later acquired or went public, including LimFlow, which Inari Medical bought for $415 million in 2023, and Calliditas Therapeutics, which Asahi Kasei acquired for more than $1 billion in 2024.

For allocators, crossover strategies sit between venture and public equity and depend on a working exit window. An above-target close for a Europe-focused vehicle suggests LPs see late-stage biotech financing gaps on the continent as an opportunity rather than a warning sign.

This entry was posted in Venture Capital and tagged , , , , , , . Bookmark the permalink.

Comments are closed.